Digital Therapeutics for Nicotine Dependence

Digital therapeutics (DTx) is a promising approach for treating nicotine dependence in Asian countries. Several nations have integrated DTx evaluation frameworks into their insurance systems, acknowledging their medical value and wide applicability. This review examines worldwide clinical research on DTx for nicotine dependence. The review includes case studies that provide an overview of DTx for nicotine dependence in the US, Germany and Japan, and detail product and treatment outcomes. Despite numerous reports showing favourable results with DTx, these therapies require usability and user cooperation, which differ from traditional medication adherence. Smoking cessation treatments should consider several factors, including patient age, smoking tools used and environmental factors. As clinical evidence accumulates, DTx has become a viable treatment option in addition to conventional therapies for treating nicotine dependence. Although some barriers still exist to its widespread use, the authors of this review look forward to further studies promoting the adoption of DTx in various countries with diverse populations.